Company News & Media

Sharing Our Journey of Innovation and Growth.

At JY BioMed, we are committed to transparency, open communication, and sharing our progress with the broader community.

Through our Company News & Media section, we provide updates on major corporate developments, partnership announcements, key research milestones, and media coverage featuring our work. We believe that consistent and accurate communication fosters trust with our stakeholders, including patients, partners, investors, and the scientific community. Follow our journey as we continue to advance our mission to transform healthcare through scientific innovation and responsible growth.

All information shared is intended for informational purposes and reflects the company’s official communications.

JY BioMed Collaborates with YC Biotech to Advance Stem Cell-Based Clinical Trial for Alzheimer’s Disease at Taipei Medical University

JY BioMed is pleased to announce that, in collaboration with our clinical development partner YC Biotech, we have officially initiated preparations for a stem cell-based clinical trial targeting Alzheimer’s disease at Taipei Medical University. The trial protocol has been commissioned and is progressing steadily toward regulatory submission and formal IRB review.

Jun 13

JY BioMed Receives FDA IND Clearance for Umbilical Cord-Derived MSC Investigational Study

JY BioMed today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for its umbilical cord-derived mesenchymal stem cell (UC-MSC) program. The clearance, issued by the Center for Biologics Evaluation and Research (CBER), allows the company to proceed with a first-in-human study under IND number 031083.0.

Apr 23

JY BioMed and YC Biotech Submit Parkinson’s Disease Regenerative Medicine Trial Proposal to TMU Joint IRB

JY BioMed Co., Ltd. and YC Biotech Co., Ltd. are pleased to announce the formal submission of a regenerative medicine clinical research proposal for Parkinson’s disease to the Joint Institutional Review Board (IRB) of Taipei Medical University and its affiliated hospitals.

Apr 11

2 3 4 5

Regulatory Disclaimer

Company news and media updates are for informational purposes only. Statements may contain forward-looking information subject to risks and uncertainties. Actual outcomes may differ from those projected.

< Back